{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:31:09Z","timestamp":1753356669106,"version":"3.40.5"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Craif Inc."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is an intractable neuromuscular disorder primarily caused by homozygous deletions in exon 7 of the<jats:italic>SMN1<\/jats:italic>gene. Early diagnosis and prompt treatment of patients with SMA have a significant impact on prognosis, and several therapies have recently been developed. Current SMA screening tests require a significant turnaround time to identify patients with suspected SMA, due both to the interval between the birth of a newborn and the collection of blood for newborn mass screening and the difficulty in distinguishing between<jats:italic>SMN1<\/jats:italic>and<jats:italic>SMN2<\/jats:italic>, a paralog gene that requires testing in specialized laboratories. The aim of this study was therefore to develop a novel SMA screening assay that can be rapidly performed in ordinary hospitals and clinics to overcome these issues. We designed over 100 combinations of forward and reverse primers with 3\u2032 ends targeting<jats:italic>SMN1<\/jats:italic>-specific sites around exon 7, and evaluated their specificity and amplification efficiency by quantitative PCR to identify the best primer pair. Furthermore, we performed a single-stranded tag hybridization assay after PCR. To evaluate the accuracy and practicality of the newly developed assay, we analyzed saliva specimens from five patients with SMA and two SMA carriers collected in an outpatient clinic and DNA specimens from three patients with SMA and four SMA carriers from a biobank, together with those from healthy individuals. DNA and raw saliva specimens from all patients with SMA demonstrated a biallelic loss of<jats:italic>SMN1<\/jats:italic>, whereas those from carriers and healthy individuals did not. The results of 50 independent experiments were consistent for all samples. The assay could be completed within one hour. This simple and convenient new screening tool has the potential to allow patients with SMA to receive disease-modifying therapies within a shorter timeframe.<\/jats:p>","DOI":"10.1371\/journal.pone.0308179","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T17:45:12Z","timestamp":1722534312000},"page":"e0308179","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["A rapid and easy-to-use spinal muscular atrophy screening tool based on primers with high specificity and amplification efficiency for SMN1 combined with single-stranded tag hybridization assay"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1696-2194","authenticated-orcid":true,"given":"Masaki","family":"Hirano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Sahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Natsume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"pone.0308179.ref001","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"S Lefebvre","year":"1995","journal-title":"Cell"},{"key":"pone.0308179.ref002","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.braindev.2021.08.002","article-title":"Epidemiological investigation of spinal muscular atrophy in Japan","volume":"44","author":"M Ito","year":"2022","journal-title":"Brain Dev"},{"key":"pone.0308179.ref003","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"EA Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"pone.0308179.ref004","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"RS Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0308179.ref005","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"JR Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0308179.ref006","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): A phase 3, double-blind, randomised, placebo-controlled trial.","volume":"21","author":"E Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"key":"pone.0308179.ref007","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"DC De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"pone.0308179.ref008","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1172\/JCI121658","article-title":"Two breakthrough gene-targeted treatments for spinal muscular atrophy: Challenges remain","volume":"128","author":"CJ Sumner","year":"2018","journal-title":"J Clin Invest"},{"key":"pone.0308179.ref009","doi-asserted-by":"crossref","first-page":"100908","DOI":"10.1016\/j.ymgmr.2022.100908","article-title":"Newborn screening for spinal muscular atrophy in Japan: One year of experience","volume":"32","author":"T Sawada","year":"2022","journal-title":"Mol Genet Metab Rep"},{"key":"pone.0308179.ref010","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.braindev.2023.03.004","article-title":"Newborn screening for spinal muscular atrophy in Osaka -challenges in a Japanese pilot study","volume":"45","author":"T Kimizu","year":"2023","journal-title":"Brain Dev"},{"key":"pone.0308179.ref011","doi-asserted-by":"crossref","first-page":"100973","DOI":"10.1016\/j.ymgmr.2023.100973","article-title":"Gene therapy for spinal muscular atrophy is considerably effective when administered as early as possible after birth","volume":"35","author":"T Sawada","year":"2023","journal-title":"Mol Genet Metab Rep"},{"key":"pone.0308179.ref012","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"UR Monani","year":"1999","journal-title":"Hum Mol Genet"},{"key":"pone.0308179.ref013","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41431-019-0476-4","article-title":"High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR","volume":"28","author":"L Czibere","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"pone.0308179.ref014","doi-asserted-by":"crossref","first-page":"180323","DOI":"10.1155\/2014\/180323","article-title":"Rapid and sensitive PCR-dipstick DNA chromatography for multiplex analysis of the oral microbiota","volume":"2014","author":"L Tian","year":"2014","journal-title":"Biomed Res Int"},{"key":"pone.0308179.ref015","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JND-190428","article-title":"One year of newborn screening for SMA\u2014Results of a German Pilot project.","volume":"6","author":"K Vill","year":"2019","journal-title":"J Neuromuscul Dis."},{"key":"pone.0308179.ref016","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn screening for spinal muscular atrophy in Germany: Clinical results after 2 years.","volume":"16","author":"K Vill","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"pone.0308179.ref017","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.nmd.2006.08.011","article-title":"Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy","volume":"16","author":"EL Arkblad","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"pone.0308179.ref018","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1373\/clinchem.2018.293712","article-title":"Multiplex droplet digital PCR method applicable to newborn screening, carrier status, and assessment of spinal muscular atrophy","volume":"64","author":"N Vidal-Folch","year":"2018","journal-title":"Clin Chem"},{"key":"pone.0308179.ref019","doi-asserted-by":"crossref","first-page":"1095600","DOI":"10.3389\/fgene.2023.1095600","article-title":"Technical feasibility of newborn screening for spinal muscular atrophy by next-generation DNA sequencing","volume":"14","author":"BOV Shum","year":"2023","journal-title":"Front Genet"},{"key":"pone.0308179.ref020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","article-title":"Presymptomatic diagnosis of spinal muscular atrophy through newborn screening","volume":"190","author":"YH Chien","year":"2017","journal-title":"J Pediatr"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T15:37:38Z","timestamp":1732549058000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0308179"}},"subtitle":[],"editor":[{"given":"Massimo","family":"Caputi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0308179","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}